PP405 is progressing rapidly through trials, with mixed opinions on its potential effectiveness. Current treatments like minoxidil and finasteride are still widely discussed, with some users reporting positive results from new formulations.
The conversation discusses creating a personalized topical treatment for hair loss, with ingredients like finasteride, minoxidil, tretinoin, melatonin, caffeine, and others. Users share their ideal formulations, including combinations of minoxidil, finasteride, tretinoin, adenosine, and other compounds, while also discussing the importance of managing inflammation.
Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.
The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.